Advertisement

Tumor Biology

, Volume 32, Issue 4, pp 689–695 | Cite as

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

  • Juan Wang
  • Ning Zhang
  • Baosheng Li
  • Zhongtang Wang
  • Hongfu Sun
  • Yan Yi
  • Wei Huang
Research Article

Abstract

We investigated the predictive value of decline in the serum levels of tumor markers on tumor response during the chemoradiotherapy (CRT) in patients with non-small cell lung cancer (NSCLC). The serum levels of cytokeratin 19 fragment antigen 21–1 (CYFRA21-1), neurone-specific enolase and carcinoembryonic antigen were measured by enzyme-linked immunosorbent assays, while the tumor responses were assessed according to the World Health Organization response criteria. The relationship between the changes of serum level of tumor markers and the radiologic response were analyzed. The effective rates (CR + PR) in CYFRA21-1 (pretreatment serum level) high and low groups were 45.8% (33/72) and 66.7% (24/36), respectively (p = 0.032). Independent sample t test showed that the relationship between the response of CYFRA21-1 and the radiologic objective response are significantly different (p = 0.008). The best cutoff value of the decline ratio of CYFRA21-1 was established as 18.48% by ROC curve. CYFRA 21–1 responses appeared to be reliable surrogate markers to predict chemoradiotherapy efficacy in patients with NSCLC, an average drop of 18.48% in serum CYFRA21-1 appears to provide the predictive information for the sensitivity of CRT.

Keywords

Chemoradiotherapy Predict CYFRA21-1 Non-small cell lung cancer 

Notes

Conflicts of interest

None

References

  1. 1.
    Ihde DC, Bunn PA, Hansen HH. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: how useful are they? J Clin Oncol. 1997;8:2996–3018.Google Scholar
  2. 2.
    Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Ebert W, Muley T. CYFRA 21–1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res. 1999;19:2669–72.PubMedGoogle Scholar
  4. 4.
    van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinter TAW. Disease monitoring by tumour markers cyfra 21–1 and TPA in patients with non small cell lung cancer. Eur J Cancer. 1995;31A:1790–3.PubMedGoogle Scholar
  5. 5.
    Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys. 2001;51:56–61.PubMedGoogle Scholar
  6. 6.
    Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Clinical value of serum cytokeratin 19 fragment and Sialyl-Lewis X in non-small cell lung cancer. Ann Thorac Surg. 2007;83:216–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Holdenrieder S, Stieber P, Von Pawel J, Raith H, Nagel D, Feldmann K, et al. Early and specific prediction of therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragment. Ann NY Acad Sci. 2006;1075:244–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Mizuguchi S, Inoue K, Iwata T, et al. High serum concentrations of Sialyl Lewis(x) predict multilevel N2 disease in non-small-cell lung cancer. Ann Surg Oncol. 2006;13:1010–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer. 1995;13:169–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Pujol JL, Molinier O, Ebert W, et al. CYFRA 21–1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097–105.PubMedGoogle Scholar
  11. 11.
    Stieber P, Hasholzner U, Bodenmuller H, et al. CYFRA 21–1. A new marker in lung cancer. Cancer. 1993;72:707–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178–84.PubMedGoogle Scholar
  13. 13.
    Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer. 1997;33:385–91.PubMedGoogle Scholar
  14. 14.
    Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiothér. 2002;6:209–16.PubMedGoogle Scholar
  16. 16.
    de Castro J, Rodríguez MC, Martínez-Zorzano VS, Hernández-Hernández A, Llanillo M, Sánchez-Yagüe J. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21–1. Cancer Investig. 2008;26:407–18.CrossRefGoogle Scholar
  17. 17.
    Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer. 2007;58:369–75.PubMedCrossRefGoogle Scholar
  18. 18.
    Buccheri G, Ferrigno D. Lung tumormarkers of cytokeratin origin: an overview. Lung Cancer. 2001;34 Suppl 2:S65–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Fischer JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer. 2004;45 Suppl 2:S151–161.PubMedCrossRefGoogle Scholar
  20. 20.
    Plabani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improbe the results? Br J Cancer. 1995;72:170–3.CrossRefGoogle Scholar
  21. 21.
    Schalhorn A, Fuerst H, Stieber P. Tumor markers in lung cancer. J Lab Med. 2001;25:353–61.Google Scholar
  22. 22.
    Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer. 2006;107:2842–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Nieder C, Andratschke N, Jeremic B, Molls M. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res. 2003;23:5117–23.PubMedGoogle Scholar
  24. 24.
    Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA125, CYFRA 21–1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209–18.PubMedCrossRefGoogle Scholar
  25. 25.
    Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21–1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene. 2003;22:6629–38.CrossRefGoogle Scholar
  27. 27.
    Ochnio J, Rogińska E, Kwiek S, Rowinska-Zakrzewska E. Wartośćoznaczania poziomu antygenu karcinoembrionalnego w surowicy krwi dla rozpoznania raka płuca, oceny jego rozległości i określenia rokowania u chorych leczonych zachowawczo. Pneumonol Pol. 1984;52:313–9.PubMedGoogle Scholar
  28. 28.
    Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21–1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer. 1998;82:1850–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer. 1986;57:1318–23.PubMedCrossRefGoogle Scholar
  30. 30.
    Buccheri G, Ferrigano D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19–9. Cancer. 1987;60:42–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994;7:1350–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Lai R, Hsu H, Lu JY, Ger LP, Lai NS. CYFRA21-1 enzyme-linked immunosorbent assay. Chest. 1996;109:995–1000.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugama Y, Kitamura S, Kawai T, Ohkubo A, Hasegawa S, Kuriyama T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res. 1994;85:1178–84.PubMedGoogle Scholar
  34. 34.
    Bréchot JM, Chevret S, Nataf J, Le Gall C, Frétault J, Rochemaure J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumourmarkers in patients with non-small cell lung cancer: a prospective study. Eur J Cancer. 1997;33:385–91.PubMedGoogle Scholar
  35. 35.
    Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer. 2005;49:1–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ. Christenson RH Serum CYFRA 21–1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res. 2003;9:1728–33.PubMedGoogle Scholar
  37. 37.
    Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non–small cell lung cancer. Clin Cancer Res. 2004;10:5981–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  • Juan Wang
    • 1
  • Ning Zhang
    • 2
  • Baosheng Li
    • 1
  • Zhongtang Wang
    • 1
  • Hongfu Sun
    • 1
  • Yan Yi
    • 1
  • Wei Huang
    • 1
  1. 1.Department of Radiation OncologyShandong Cancer Hospital and InstituteJinanPeople’s Republic of China
  2. 2.Department of Joint SurgeryThe First Hospital of Jilin UniversityChangchunPeople’s Republic of China

Personalised recommendations